Aptus Capital Advisors LLC Has $33.58 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aptus Capital Advisors cut its Thermo Fisher Scientific stake by 91.2% in the fourth quarter, leaving it with 57,944 shares valued at about $33.6 million.
• Thermo Fisher continues to see broad institutional support, with 89.23% of shares held by institutions and hedge funds; several large investors, including Norges Bank and Wellington Management, also boosted or initiated major positions.
• Analysts are still broadly positive but have trimmed expectations: the stock has a Moderate Buy consensus and a $608.95 average price target, while the company recently beat quarterly earnings estimates and raised FY2026 EPS guidance.

Aptus Capital Advisors LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 91.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,944 shares of the medical research company's stock after selling 598,243 shares during the quarter. Aptus Capital Advisors LLC's holdings in Thermo Fisher Scientific were worth $33,576,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Norges Bank acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $3,072,744,000. Wellington Management Group LLP grew its stake in Thermo Fisher Scientific by 88.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock valued at $1,309,292,000 after buying an additional 1,270,191 shares during the last quarter. Franklin Resources Inc. grew its stake in Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock valued at $2,874,069,000 after buying an additional 1,028,125 shares during the last quarter. Nuveen LLC boosted its holdings in Thermo Fisher Scientific by 65.0% in the 4th quarter. Nuveen LLC now owns 2,147,296 shares of the medical research company's stock valued at $1,244,251,000 after purchasing an additional 846,111 shares during the period. Finally, Corient Private Wealth LLC boosted its holdings in Thermo Fisher Scientific by 89.1% in the 2nd quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company's stock valued at $720,576,000 after purchasing an additional 825,649 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TMO. HSBC downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Barclays reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a report on Tuesday, April 14th. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a report on Friday, April 24th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target for the company. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $608.95.

Thermo Fisher Scientific Trading Down 1.4%

Shares of Thermo Fisher Scientific stock opened at $468.80 on Friday. The stock has a market capitalization of $174.22 billion, a P/E ratio of 25.77, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a 50-day simple moving average of $479.14 and a 200 day simple moving average of $527.68. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.34%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.